Duopharma is seen as a proven defensive shelter amid financial and economic uncertainties.
PETALING JAYA: As the Covid-19 pandemic hype diminishes, Duopharma Biotech Bhd
’s strong execution and consistent earnings growth should eventually lead to a re-rating.
Duopharma is seen as a proven defensive shelter amid financial and economic uncertainties.
Already a subscriber? Log in.
Subscribe now and receive FREE sooka plan for 1 month.
T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
